Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.

This novel nomogram was more accurate, and achieved higher net benefit than APRI, NFS, FIB-4 and BARD to detect significant fibrosis. It can be useful as a non-invasive method to screen ≥F2 fibrosis in the overall population with NAFLD.